Amgen Inc. (AMGN) Stock Rises on Strong Q3 Performance and Revenue Growth
Amgen Inc. (AMGN) saw its stock price edge higher, closing at $296.70, as investors reacted to robust third-quarter results. Revenue surged 12% year-over-year to $9.6 billion, driven by a 14% volume increase across its product portfolio. Key performers included Repatha® and TEPEZZA®, with the former posting a 40% sales jump.
Operating income climbed 25%, while free cash FLOW reached $4.2 billion—a marked improvement. The company's diversified therapeutic offerings, spanning oncology and inflammation, underscore its market resilience. Amgen projects 2025 revenues between $35.8 billion and $36.6 billion, signaling confidence in sustained growth.